ABCL vs NSC · rev $12.4M vs P/E 18, rev $6.46B
Abcellera Biologics Inc (ABCL) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported NSC revenue for 2026-06-30 was $6.46B. Net income was $1.28B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
ABCL currently screens at market cap $1.12B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the ABCL and NSC stock pages for the full models.
Not investment advice.